Last reviewed · How we verify
NCT02449213
A Biobehavioral Model of Diabetes Risk in Chinese Immigrants
trial in Diabetes Mellitus, Type 2 in 650 participants. Completed in 5 May 2021.
5 May 2021
Quick facts
| Lead sponsor | Fox Chase Cancer Center |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 650 |
| Start date | 11 March 2016 |
| Primary completion | 5 May 2021 |
| Estimated completion | 5 May 2021 |
| Sites | 1 location across United States |
Conditions studied
- Diabetes Mellitus, Type 2 — all drugs for Diabetes Mellitus, Type 2 →
Sponsor
Fox Chase Cancer Center — full company profile →
Who can join
Adults 35 to 65, any sex, with Diabetes Mellitus, Type 2. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This prospective, longitudinal study of Chinese American immigrants will examine whether psychosocial factors (e.g., acculturative stress, social isolation, discrimination) are associated with markers of type 2 diabetes risk over time, and whether such associations are mediated by inflammatory pathways.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Increases in Psychological Stress Are Associated With Higher Fasting Glucose in US Chinese Immigrants.
Fang CY, Rao A, Handorf EA, Deng M, et al · · 2024 · PMID 39316655 · DOI 10.1093/abm/kaae056
Verify or expand the search:
- PubMed search for NCT02449213
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Diabetes Mellitus, Type 2
Currently open trials in the same condition.
- NCT07415954 — A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 · Phase 2 · recruiting
- NCT07532863 — A Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Part · recruiting
- NCT07336329 — Continuous Glucose Monitoring in Non-Insulin Treated Type 2 Diabetes: Continuous vs. Periodic Use · NA · recruiting
- NCT07242469 — A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006) · Phase 1 · recruiting
- NCT07444203 — Transformative Research in Diabetic Nephropathy 2.0 · recruiting
Other Fox Chase Cancer Center trials
Trials by the same sponsor.
- NCT07455032 — Neoadjuvant CADI-05 in Combination With Pembrolizumab for Surgically Resectable Locally Advanced Head and Neck Squamous · Phase 1 · recruiting
- NCT07221942 — Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial Carcinoma · Phase 2 · recruiting
- NCT07221058 — Adaptive Radiation Boost for Rectal Cancer · Phase 1 · recruiting
- NCT07167446 — Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy · EARLY_PHASE1 · recruiting
- NCT07219303 — Adaptive Radiation Therapy for Men With Intermediate- or High-Risk Prostate Cancer · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02449213 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fox Chase Cancer Center
- Last refreshed: 4 June 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02449213.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing